Skip Navigation LinksHome > October 2013 - Volume 33 - Issue 9 > FEASIBILITY OF A NOVEL REMOTE DAILY MONITORING SYSTEM FOR AG...
Retina:
doi: 10.1097/IAE.0b013e3182899258
Original Study

FEASIBILITY OF A NOVEL REMOTE DAILY MONITORING SYSTEM FOR AGE-RELATED MACULAR DEGENERATION USING MOBILE HANDHELD DEVICES: Results of a Pilot Study

Kaiser, Peter K. MD*; Wang, Yi-Zhong PhD†,‡; He, Yu-Guang MD; Weisberger, Annemarie MD§; Wolf, Stephane MBA; Smith, Craig H. MD**

Supplemental Author Material
Collapse Box

Abstract

Purpose:

This pilot study evaluated the feasibility of the Health Management Tool (HMT), a novel computing system using mobile handheld devices, to remotely monitor retinal visual function daily in patients with neovascular age-related macular degeneration treated with ranibizumab.

Methods:

Patients with neovascular age-related macular degeneration in at least 1 eye (newly diagnosed or successfully treated < 1 year) and eligible for ranibizumab therapy were enrolled in this 16-week, prospective, open-label, single-arm study. Patients performed a shape discrimination hyperacuity test (myVisionTrack [mVT]) daily on the HMT device (iPhone 3GS) remotely and at all clinic visits. Data entered into HMT devices were collected in the HMT database, which also sent reminders for patients to take mVT.

Results:

Among 160 patients from 24 U.S. centers enrolled in the study (103 [64%] ≥75 years of age), 84.7% on average complied with daily mVT testing and ∼98.9% complied with at least weekly mVT testing. The HMT database successfully uploaded more than 17,000 mVT assessment values and sent more than 9,000 reminders.

Conclusion:

Elderly patients with neovascular age-related macular degeneration were willing and able to comply with daily self-testing of retinal visual function using mobile handheld devices in this novel system of remote vision monitoring.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.